Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Fruquintinib

(Fruzaqla®)

Fruzaqla®

Drug updated on 12/11/2024

Dosage FormCapsule (oral; 1mg, 5mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine, oxaliplatin, and irinotecanbased chemotherapy, an antiVEGF therapy, and, if RAS wildtype and medically appropriate, an anti-EGFR therapy.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of six systematic review(s)/meta-analysis(es). [1-6]
  • Fruquintinib demonstrated improved overall survival (OS) compared to Best Supportive Care (BSC), with results comparable to trifluridine/tipiracil (TAS-102) and regorafenib, although no significant differences in OS were observed among these drugs in some studies.
  • Fruquintinib showed superior Progression-Free Survival (PFS) compared to BSC and exhibited better PFS in specific subgroups, such as patients with wild-type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS). Fruquintinib also demonstrated significant superiority for PFS compared with TAS-102 in several studies.
  • Fruquintinib was associated with an improved disease control rate (DCR) compared to TAS-102, with relative superiority in terms of achieving disease control in several reports.
  • Fruquintinib was associated with a higher incidence of serious adverse events (SAES) compared to TAS-102 or regorafenib.
  • There were no significant differences in the incidence of all-grade adverse events (AES) or grade 3-5 AEs among fruquintinib, TAS-102, and regorafenib, as observed in multiple documents.
  • Subgroup analysis showed that TAS-102 plus bevacizumab ranked first in OS benefit across various subgroups, including age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, and time from initial diagnosis of metastatic disease. Document 4 noted that fruquintinib demonstrated better progression-free survival (PFS) in the wild-type KRAS subgroup compared to other treatments, with good tolerability.